Glycemic control, as measured by changes in glycated hemoglobin levels, remains an acceptable primary efficacy end point for approval of drugs to treat hyperglycemia, the agency states.

• 经销商认为，通过糖化血红蛋白水平的改变来衡量的甘油酯治疗，对于允许该药用于高血糖的治疗，仍是一个可接受的主要有效终点。